PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2839116-6 1988 A current study comparing the standard chemotherapy with cyclophosphamide, adriamycin and vincristine (CAV) to alternating CAV with etoposide (E) and cisplatin (P) has suggested an advantage for alternating chemotherapy, with a statistically superior response rate and survival. Cyclophosphamide 57-73 caveolin 2 Homo sapiens 103-106 1056807-2 1975 Cyclophosphamide, cytosine arabinoside and vincristine (CAV) therapy resulted in complete remission in 23 of 50 previously untreated patients with AML and in 3 of the 11 patients with CML. Cyclophosphamide 0-16 caveolin 2 Homo sapiens 56-59 2820571-2 1987 The effectiveness of both cyclophosphamide, doxorubicin, and vincristine (CAV) and etoposide and cisplatin (VPP) in previously untreated patients with small cell lung cancer has been well-documented. Cyclophosphamide 26-42 caveolin 2 Homo sapiens 74-77 3020704-5 1986 In addition, combination chemotherapy studies using etoposide have yielded toxicity equivalent to IV administered programs such as CAV (cyclophosphamide, doxorubicin, vincristine). Cyclophosphamide 136-152 caveolin 2 Homo sapiens 131-134 16532434-2 2006 The authors report on their results from a regimen of ifosfamide, carboplatin, and etoposide (ICE) with cyclophosphamide, doxorubicin, and vincristine (CAV) dose intensification in patients with high-risk ESFT. Cyclophosphamide 104-120 caveolin 2 Homo sapiens 152-155 2201427-7 1990 The authors" patient was correctly diagnosed during life and received considerable benefit from cyclophosphamide, doxorubicin, and vincristine (CAV) therapy and survived for 26 months after diagnosis. Cyclophosphamide 96-112 caveolin 2 Homo sapiens 144-147 10422440-16 1999 Although 2 cycles of CAV/PE therapy with cyclophosphamide, doxorubicin, vincristine, CDDP, and VP-16 were performed following resection of the retroperitoneal tumor, he showed no response and decreased 24 months after surgery. Cyclophosphamide 41-57 caveolin 2 Homo sapiens 21-27 1656891-2 1991 He was treated three times with CAV (cyclophosphamide, doxorubicin, vincristine) therapy and a partial response was achieved. Cyclophosphamide 37-53 caveolin 2 Homo sapiens 32-35 1648333-1 1991 Both CAV (Cyclophosphamide, Doxorubicin, Vincristine) and PE (Cisplatin, Etoposide) are effective and non cross-resistant regimens in the treatment of SCLC. Cyclophosphamide 10-26 caveolin 2 Homo sapiens 5-8 9626212-6 1998 CAV/PE consisted of cyclophosphamide 800 mg/m2; doxorubicin 50 mg/m2; and vincristine 1.4 mg/m2 on day 1, which alternated every 3 weeks with cisplatin 80 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1 to 3. Cyclophosphamide 20-36 caveolin 2 Homo sapiens 0-6 9597676-3 1998 Either PE (platinum plus etoposide) or CAV (cyclophosphamide, Adriamycin, and vincristine) is a reasonable first-line therapy. Cyclophosphamide 44-60 caveolin 2 Homo sapiens 39-42 8751797-2 1996 Combination chemotherapy with cisplatin/etoposide (PE) or CAV (cyclophosphamide, adriamycin and vincristine) alternating with PE was established as standard regimens. Cyclophosphamide 63-79 caveolin 2 Homo sapiens 58-61 2175049-0 1990 Treatment of small cell lung cancer with cyclophosphamide, adriamycin and vincristine (CAV) combination therapy: experience at University Hospital, Kuala Lumpur, Malaysia. Cyclophosphamide 41-57 caveolin 2 Homo sapiens 87-90 2153765-1 1990 The present randomized, prospective study was designed to assess whether alternating induction cyclophosphamide, doxorubicin, vincristine-altretamine (hexamethylmelamine), etoposide, and methotrexate (CAV-HEM) chemotherapy is better than standard chemotherapy (CAV) in improving response, survival, and remission time in 577 evaluable patients having extensive-disease small-cell lung cancer (SCLC). Cyclophosphamide 95-111 caveolin 2 Homo sapiens 201-204 2154857-2 1990 Twenty-five patients had prior exposure to cisplatin plus etoposide, and 14 of the 26 patients (54%) had prior therapy with CAV (cyclophosphamide, doxorubicin, and vincristine). Cyclophosphamide 129-145 caveolin 2 Homo sapiens 124-127